** Drug developer Dermata Therapeutics' DRMA.O shares rise 8.2% to $1.46 premarket

** Company says its experimental drug xyngari meet primary main goal to treat moderate-to-severe acne in a late-stage study

** Main goals of the late-stage study were to measure the average change in both inflammatory and non-inflammatory skin blemishes and to assess the treatment response using a common scale called Investigator Global Assessment $(IGA)$

** Company says xyngari showed "highly statistically significant and clinically meaningful improvement" in acne compared to placebo after 12 weeks of once-weekly treatment

** Company says it is set to launch the drug in H2 2025

** As of last close, Dermata's shares down ~78% in past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))